Genetic and environmental epidemiology of Alzheimer’s disease in arabs residing in Israel Lindsay A. FarrerRobert P. FriedlandClinton T. Baldwin Genetics And Prevention Pages: 207 - 212
Enhancing brain and cognitive function of older adults through fitness training Arthur F. KramerStanley J. ColcombeAndrew G. Webb Genetics And Prevention Pages: 213 - 221
Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites Shyamala MruthintiWilliam D. HillJerry J. Buccafusco Target Identification And Validation Pages: 223 - 232
β-secretase processing of the Alzheimer’s amyloid protein precursor (APP) Laura MarlowMelissa CainKumar Sambamurti Target Identification And Validation Pages: 233 - 239
Hippocampal volume is associated with memory but not nonmemory cognitive performance in patients with mild cognitive impairment Michael GrundmanClifford R. Jackthe Alzheimer’s Disease Cooperative Study Early Detection Pages: 241 - 248
Characterization of radioiodinated ligand binding to amyloid β plaques Mei-Ping KungZhi-Ping ZhuangHank F. Kung Early Detection Pages: 249 - 253
Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives Yanming WangChester A. MathisWilliam E. Klunk Early Detection Pages: 255 - 260
Peptide nucleic acids targeted to the amyloid precursor protein Beth M. McMahonJennifer StewartElliott Richelson Alzheimer’s Therapeutics: Anti-Amyloid Pages: 261 - 265
Drug discovery targeted to the Alzheimer’s APP mRNA 5′-untranslated region Sandra PaytonCatherine M. CahillJack T. Rogers Alzheimer’s Therapeutics: Anti-Amyloid Pages: 267 - 275
Potential use of estrogen-like drugs for the prevention of Alzheimer’s disease Jonathan D. SmithJustine A. Levin-Allerhand Alzheimer’s Therapeutics: Anti-Amyloid Pages: 277 - 281
Immunological approach for the treatment of Alzheimer’s disease Beka Solomon Alzheimer’s Therapeutics: Anti-Amyloid Pages: 283 - 286
The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer’s disease Jerry P. MelchorRobert PawlakSidney Strickland Alzheimer’s Therapeutics: Anti-Amyloid Pages: 287 - 289
Novel glycosaminoglycan precursors as anti-amyloid agents, Part III Robert KisilevskyWalter A. SzarekSandra Marone Alzheimer’s Therapeutics: Anti-Amyloid Pages: 291 - 297
Study of memapsin 2 (β-secretase) and strategy of inhibitor design Jordan TangArun K. GhoshWanpin Chang Alzheimer’s Therapeutics: Anti-Amyloid Pages: 299 - 304
Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening Lei ChangLara BakhosWilliam L. Klein Alzheimer’s Therapeutics: Anti-Amyloid Pages: 305 - 313
From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP Illana GozesInna DivinskyAvron D. Spier Alzheimer’s Therapeutics: Neuroprotection Pages: 315 - 322
Alzheimer’s therapeutics Stephen M. MassaYoumei XieFrank M. Longo Alzheimer’s Therapeutics: Neuroprotection Pages: 323 - 326
Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer’s disease Marcos A. MarquesKeith A. Crutcher Alzheimer’s Therapeutics: Neuroprotection Pages: 327 - 337
Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors Antonie RiceMary L. MichaelisKenneth L. Audus Alzheimer’s Therapeutics: Neuroprotection Pages: 339 - 343
Structure-based rational design of chemical ligands for AMPA-subtype glutamate receptors Lei ZengCan Hao ChenMing-Ming Zhou Alzheimer’s Therapeutics: Neuroprotection Pages: 345 - 348
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease Abraham FisherZipora PittelRachel Brandeis Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 349 - 356
Calpain inhibitors, a treatment for alzheimer’s disease Fortunato BattagliaFabrizio TrincheseOttavio Arancio Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 357 - 362
Progress toward a high-affinity allosteric enhancer at muscarinic M1 receptors Sebastian LazarenoAngela PophamNigel J. M. Birdsall Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 363 - 367
Acetylcholinesterase Harry M. GreenblattHay DvirJoel L. Sussman Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 369 - 383
Steroid hormones and cognitive functioning in aging men Barbara B. Sherwin Alzheimer’s Therapeutics: Cognitive Enhancement Pages: 385 - 393
Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol Suzana S. PetanceskaSteven DeRosaMiguel Pappolla Alzheimer’s Therapeutics: Lipid Lowering Pages: 395 - 406
A position paper D. Larry SparksJean Lopezthe ADCLT Team Alzheimer’s Therapeutics: Lipid Lowering Pages: 407 - 410
Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against β-amyloid induced injury D. Martin WattersonAnastasia V. VelentzaLinda J. Van Eldik Alzheimer’s Therapeutics: Anti-Inflammation Pages: 411 - 423
Alzheimer neurofibrillary degeneration Khalid IqbalAlejandra del C. AlonsoInge Grundke-Iqbal Alzheimer’s Therapeutics: Anti-Tangle Pages: 425 - 429